Metastatic Breast Cancer
Relevance: Medium-High
Most relevant for: People with breast cancer
Update: Approval of new breast cancer drugs increases treatment options
The FDA recently approved several new breast cancer treatments. Patients and doctors now have more treatment options for advanced and early-stage breast cancer. These treatments highlight the role of biomarker testing in guiding treatment decisions. (posted 6/22/2026)
READ MORE ›
Relevance: High
Most relevant for: cancer survivors experiencing ongoing anxiety after completing treatment who are looking for accessible, effective mental health support options.
Study: Music therapy as effective as cognitive behavioral therapy for anxiety in cancer survivors
A study published in the Journal of Clinical Oncology found that music therapy delivered by telehealth worked just as well as cognitive behavioral therapy (CBT) to reduce anxiety among cancer survivors. Both approaches led to meaningful and lasting improvements, not only in anxiety, but also in sleep, fatigue and overall quality of life. These findings give patients more flexible, evidence-based options for managing emotional health after cancer. (posted 6/12/2026)
READ MORE ›
Relevance: High
Most relevant for: People who are experiencing pelvic side effects related to treatment or surgery
Article: Pelvic health therapy improves quality of life after treatment or prevention
Pelvic health therapy can significantly improve comfort, function and quality of life for people experiencing pelvic pain, bladder or bowel issues, and sexual dysfunction after cancer treatment or preventive surgery. This article highlights the importance of restoring tissue mobility, strengthening the pelvic floor and providing emotional support to empower survivors and previvors. (posted 3/23/2026)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations
Study: Treating advanced breast cancer with ESR1 mutations shows promise
Treatment with the new hormonal drug camizestrant benefited people with certain advanced breast cancers with a biomarker called an ESR1 mutation. People who participated in the SERENA6 study experienced a longer time before their cancer worsened and had a better quality of life than those who received the standard treatment. This study used a blood test to track changes in the cancer to clarify whether treatment worked before symptoms developed. (posted 2/19/26)
READ MORE ›
Relevance: High
Most relevant for: People diagnosed with cancer who require 5-FU or capecitabine treatment
Guideline: FDA recommends testing to prevent serious side effects from 5-FU and capecitabine chemotherapy
A small number of people treated with the chemotherapy drugs 5-FU (5-fluorouracil) or capecitabine (Xeloda) can have serious or even life-threatening side effects because their body breaks down the drug more slowly than is typical. A genetic test called DPYD testing can help identify people at higher risk for serious side effects before treatment starts. (posted 2/11/26)
READ MORE ›
Relevance: Medium-High
Most relevant for: People who have had or are considering liquid biopsy testing
Topic: What Patients Need to Know About Liquid Biopsies in Cancer Care
Liquid biopsies are tests that look for signs of cancer in blood or other body fluids. These signs can include cancer cells that have broken away from a tumor, pieces of cancer cell DNA and proteins or other biomarkers found in cancer cells. Liquid biopsies can be used to screen for cancer before a cancer diagnosis or guide treatment after a diagnosis. (posted 2/6/26)
READ MORE ›
Relevance: High
Most relevant for: People with an inherited mutation in ATM, BRCA1, BRCA2, CHEK2, PALB2 or a Lynch syndrome gene who have been diagnosed with breast, colorectal or pancreatic cancer
Study: Cancer patients with certain inherited mutations have cancer outcomes similar to those without inherited mutations
People with an inherited mutation in certain genes, including ATM, CHEK2, PALB2, BRCA or Lynch syndrome genes, have an increased risk of cancer. In this study, researchers wanted to know whether cancer patients with inherited mutations had a different chance of survival than patients without an inherited mutation in these genes. These results showed that, although the risk of cancer is increased, there is no difference in survival after a diagnosis of breast, pancreatic or colorectal cancer with or without these genetic changes. (posted 11/20/25)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with breast cancer or at high-risk of breast cancer
Update: FDA in the News: FDA approvals and health information on breast cancer
This XRAY review reports new treatments approved by the FDA for early and metastatic breast cancer and educational resources about women's health. (Posted 8/4/25)
READ MORE ›
Relevance: High
Most relevant for: People with advanced or metastatic breast cancer with a PIK3CA tumor mutation.
Study: New FDA approval of Itovebi, a drug that may improve treatment for certain advanced or metastatic breast cancers
About one-third of hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancers have a PIK3CA tumor mutation that can increase cancer growth and lead to treatment resistance. A new targeted therapy, Itovebi (inavolisib), improved patient outcomes when combined with standard treatment. This led to the recent FDA approval of the drug. (Posted 7/3/25)
READ MORE ›
Relevance: High
Most relevant for: People with HR-positive metastatic breast cancer
Study: Enhertu shows promising results for HER2-low and HER2-ultralow metastatic breast cancer
Recent study results show that a new targeted treatment works better than standard chemotherapy for people with metastatic hormone receptor-positive breast cancers with low or ultralow HER2 status. (Posted 5/15/25)
READ MORE ›